Abstract
Background: Neurological manifestations such as cognitive impairment and sleep abnormalities are core symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that is a severely debilitating disease of unknown etiology. Various immune system abnormalities have been reported and recent studies revealed that two thirds of ME/CFS patients receiving B cell depletion therapy by rituximab had a clinical improvement. However, how the pathogenesis of ME/CFS is related to B cell is still unclear.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
